Lupin Ltd vs Shukra Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Lupin Ltd is ₹ 2341 as of 04 May 11:02 . The P/E Ratio of Lupin Ltd changed from 38.1 on March 2021 to 28.2 on March 2025 . This represents a CAGR of -5.84% over 5 yearsThe P/E Ratio of Shukra Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Lupin Ltd changed from ₹ 46318 crore on March 2021 to ₹ 92522 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of Shukra Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Lupin Ltd for the Dec '25 is ₹ 7282 crore as compare to the Sep '25 revenue of ₹ 7137 crore. This represent the growth of 2.03% The revenue of Shukra Pharmaceuticals Ltd for the Dec '25 is ₹ 39.95 crore as compare to the Sep '25 revenue of ₹ 7.59 crore. This represent the growth of 426.35% The ebitda of Lupin Ltd for the Dec '25 is ₹ 1949 crore as compare to the Sep '25 ebitda of ₹ 2431 crore. This represent the decline of -19.8% The ebitda of Shukra Pharmaceuticals Ltd for the Dec '25 is ₹ 27.95 crore as compare to the Sep '25 ebitda of ₹ 1.29 crore. This represent the growth of 2066% The net profit of Lupin Ltd changed from ₹ 805.54 crore to ₹ 1180 crore over 7 quarters. This represents a CAGR of 24.41% The net profit of Shukra Pharmaceuticals Ltd changed from ₹ 3.16 crore to ₹ 20.36 crore over 5 quarters. This represents a CAGR of 343.89% The Dividend Payout of Lupin Ltd changed from 23.43 % on March 2021 to 13.79 % on March 2025 . This represents a CAGR of -10.06% over 5 yearsThe Dividend Payout of Shukra Pharmaceuticals Ltd changed from 10.47 % on March 2022 to 4.57 % on March 2025 . This represents a CAGR of -18.72% over 4 years .

About Lupin Ltd

Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
The Company has significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporins segments. Lupin Limited was incorporated in the year 1983 with the name Lupin Chemicals Limited.
In March 2001, Lupin Laboratories Limited was amalgamated with the company and the name was changed to Lupin Limited.
In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar.

About Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Limited, formerly known Relish Pharmaceuticals Limited was established in March, 1993 and later on the Company name was changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective on September 22, 2016.
The Company is presently engaged in the business of manufacturing and trading of pharmaceuticals formulations and laboratory testing. The company provides varieties of products to the clientele.
Their product portfolio includes Antibiotics (Penicillin), Anti Biotics (Cephalosporin), Anti Biotics, Macrolides, Quinolones, Anti Bacterial, Anti Fungal, Anti Malarial, Anti Viral, Anti Protozoal, Anti Anthelmintic, Sedative and Tranquilliser, Anti Depressant, Anti Manic, Anti Emetic, Anti Ulcer, Beta Blockers, Diuretics, Analgesic, Analgesic (NASID), Muscle Relaxants, Anti Tuberculosis, Vitamin Products, Anti Allergics, Corticosteroids, Hyper and Hypoglycemic, Others.

FAQs for the comparison of Lupin Ltd and Shukra Pharmaceuticals Ltd

Which company has a larger market capitalization, Lupin Ltd or Shukra Pharmaceuticals Ltd?

Market cap of Lupin Ltd is 105,320 Cr while Market cap of Shukra Pharmaceuticals Ltd is 1,272 Cr

What are the key factors driving the stock performance of Lupin Ltd and Shukra Pharmaceuticals Ltd?

The stock performance of Lupin Ltd and Shukra Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Lupin Ltd and Shukra Pharmaceuticals Ltd?

As of May 4, 2026, the Lupin Ltd stock price is INR ₹2303.7. On the other hand, Shukra Pharmaceuticals Ltd stock price is INR ₹29.07.

How do dividend payouts of Lupin Ltd and Shukra Pharmaceuticals Ltd compare?

To compare the dividend payouts of Lupin Ltd and Shukra Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.